{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:56:39Z","timestamp":1793332599548,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jacc.2025.06.058","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T15:13:43Z","timestamp":1756739623000},"page":"696-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity"],"prefix":"10.1016","volume":"86","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"DiMaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth J.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5887-8161","authenticated-orcid":false,"given":"Sheldon E.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5020-7912","authenticated-orcid":false,"given":"Yang","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Koeneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.06.058_bib1","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.06.058_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.294.3.334","article-title":"Insulin resistance and risk of congestive heart failure","volume":"294","author":"Ingelsson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.06.058_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/dci17-0052","article-title":"Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes","volume":"41","author":"Packer","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.06.058_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.121.055830","article-title":"Diabetes status modifies the association between different measures of obesity and heart failure risk among older adults: a pooled analysis of community-based NHLBI cohorts","volume":"145","author":"Patel","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.058_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-021-01378-4","article-title":"Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM\/BiomarCaRE consortium","volume":"20","author":"Vuori","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.06.058_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/2047487319851298","article-title":"Threshold body mass index and sex-specific waist circumference for increased risk of heart failure with preserved ejection fraction","volume":"26","author":"Campbell","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.06.058_bib8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ejhf.3478","article-title":"Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: the EXSCEL trial","volume":"27","author":"Neves","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.058_bib9","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.058_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.058_bib11","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ejhf.1956","article-title":"Regional adiposity and heart failure with preserved ejection fraction","volume":"22","author":"Rao","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jacc.2025.06.058_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202200264","article-title":"Loss of visceral fat is associated with a reduction in inflammatory status in patients with metabolic syndrome","volume":"67","author":"Castro-Barquero","year":"2023","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.jacc.2025.06.058_bib13","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.058_bib15","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1007\/s00330-024-10658-y","article-title":"Long-term outcomes prediction in diabetic heart failure with preserved ejection fraction by cardiac MRI","volume":"34","author":"Yang","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib16","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1002\/ehf2.14929","article-title":"Coronary microvascular dysfunction and left heart filling pressures in patients with type 2 diabetes","volume":"11","author":"Wolsk","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.058_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819861593","article-title":"Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes","author":"Gulsin","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.06.058_bib18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.058_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-021-01242-5","article-title":"Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort","volume":"20","author":"Lejeune","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.06.058_bib20","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: the DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.06.058_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.06.058_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.orcp.2023.12.001","article-title":"Incidence of type 2 diabetes after gastric by-pass surgery in a Swedish controlled cohort study","volume":"18","author":"Jamaly","year":"2024","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.jacc.2025.06.058_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019323","volume":"10","author":"H\u00f6skuldsd\u00f3ttir","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.06.058_bib24","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2005.00568.x","article-title":"Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study","volume":"59","author":"Wang","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacc.2025.06.058_bib25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib27","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.06.058_bib31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacc.2025.06.058_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171245","article-title":"Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K\/Akt signaling","volume":"178","author":"Chen","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.jacc.2025.06.058_bib35","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes","volume":"38","author":"Lovshin","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.06.058_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156038","article-title":"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials","volume":"161","author":"Xie","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2025.06.058_bib38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-024-03896-z","article-title":"Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial","volume":"86","author":"Qin","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.jacc.2025.06.058_bib39","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib40","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.06.058_bib41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, a preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacc.2025.06.058_bib42","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib43","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.06.058_bib44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12968-021-00815-3","article-title":"Reference ranges (\u201cnormal values\u201d) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update","volume":"23","author":"Kawel-Boehm","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacc.2025.06.058_bib45","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-8587(22)00308-4","volume":"10","author":"Inzucchi","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.058_bib46","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ejhf.2450","article-title":"Effects of sacubitril\/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF","volume":"24","author":"Peikert","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.058_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.883615","article-title":"Diabetes is the strongest predictor of limited exercise capacity in chronic heart failure and preserved ejection fraction (HFpEF)","volume":"9","author":"Berisha-Muharremi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12933-021-01379-3","article-title":"Effect of diabetes mellitus on the development of left ventricular contractile dysfunction in women with heart failure and preserved ejection fraction","volume":"20","author":"Shi","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.06.058_bib49","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.hlc.2023.12.008","article-title":"The impact of diabetes on haemodynamic and cardiometabolic responses in heart failure with preserved ejection fraction","volume":"33","author":"Nan Tie","year":"2024","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacc.2025.06.058_bib50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12933-023-01835-2","article-title":"Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction: a case-control study in individuals aged 65-80 years","volume":"22","author":"Sugita","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.06.058_bib51","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/diagnostics11030397","article-title":"Epicardial adiposity in relation to metabolic abnormality, circulating adipocyte FABP, and preserved ejection fraction heart failure","volume":"11","author":"Lin","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jacc.2025.06.058_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4093\/dmj.2015.39.5.405","article-title":"Increased epicardial adipose tissue thickness in type 2 diabetes mellitus and obesity","volume":"39","author":"Song","year":"2015","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jacc.2025.06.058_bib54","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.058_bib55","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ejhf.1902","article-title":"Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.jacc.2025.06.058_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100657","article-title":"Uncovering the role of epicardial adipose tissue in heart failure with preserved ejection fraction","volume":"2","author":"Goldman","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacc.2025.06.058_bib57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12933-023-01738-2","article-title":"Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis","volume":"22","author":"Myasoedova","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.06.058_bib58","article-title":"Association of epicardial fat with cardiac structure and function and exercise capacity in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"54","author":"Fukuta","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jacc.2025.06.058_bib59","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.3390\/jcm13185533","article-title":"Epicardial fat in heart failure with preserved ejection fraction compared with reduced ejection fraction","volume":"13","author":"Sidhu","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.06.058_bib60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4330\/wjc.v16.i3.149","article-title":"Epicardial adipose tissue in obesity with heart failure with preserved ejection fraction: Cardiovascular magnetic resonance biomarker study","volume":"16","author":"Shao","year":"2024","journal-title":"World J Cardiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib61","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/ejhf.2709","article-title":"Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS-HFpEF study","volume":"24","author":"Venkateshvaran","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.058_bib62","first-page":"625","article-title":"Epicardial adipose tissue in heart failure phenotypes\u2014a meta-analysis","volume":"118","author":"Correia","year":"2022","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib63","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/ejhf.2337","article-title":"Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure","volume":"23","author":"Pugliese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.058_bib64","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jchf.2020.06.003","article-title":"Epicardial adipose tissue and invasive hemodynamics in heart failure with preserved ejection fraction","volume":"8","author":"Gorter","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.058_bib65","article-title":"Epicardial adipose tissue and exercise intolerance in HFpEF","volume":"54","author":"Lobeek","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jacc.2025.06.058_bib66","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jacc.2024.05.065","article-title":"Effect of semaglutide on epicardial adipose tissue in type 2 diabetes: insights from the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) randomized trial","volume":"84","author":"Manubolu","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib67","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00592-014-0710-z","article-title":"Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study","volume":"52","author":"Morano","year":"2015","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jacc.2025.06.058_bib68","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.058_bib69","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/eurjpc\/zwad050","article-title":"Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies","volume":"30","author":"Malavazos","year":"2023","journal-title":"Eur J Prev Cardiol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725070962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725070962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T15:50:07Z","timestamp":1756741807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725070962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0735109725070962"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.06.058","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.06.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}